MonumentTAL-3: 64407564MMY3002: A Phase III Randomized Study Comparing Talquetamab SC in Combination with Daratumumab SC and Pomalidomide Tal-DP or Talquetamab SC in Combination with Daratumumab SC Tal-D versus Daratumumab SC, Pomalidomide and Dexamethasone DPd, in Participants with Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

Brief Summary

Type:
Multiple Myeloma

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05455320

Study #:
STUDY00149572

Start Date:
Oct 09, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05455320

View Complete Trial Details & Eligibility at ClinicalTrials.gov